SOTYKTU DIN 02533030
Health Canada record
| Active ingredient(s) | DEUCRAVACITINIB 6 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L04AF07 DEUCRAVACITINIB |
| Original market date | 14-Feb-2023 |
| Current status date | 14-Feb-2023 |
| Source | Health Canada DPD |
Establishment licence of the holder
Bristol-Myers Squibb Canada — licence 100100, currently licensed, last inspection rating C (2026-03-18).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 29540 | 2022-11-24 | New Drug Submission (NDS) |
International API supply for DEUCRAVACITINIB
15 active FDA Drug Master Files.
Request a quote for SOTYKTU